Table 5 Details of numbers of dogs, pre- and post- treatment seizure frequency, period of treatment, doses of AED(s), seizure frequency reduction/response after the initiation of treatment and efficacy statements for each study
References | Boothe et al.[11] | Schwartz-Porsche et al.[28] | Trepanier et al.[34] | Podell et al.[33] | Pearce[32] | |
|---|---|---|---|---|---|---|
AED evaluated | Potassium bromide | |||||
2 nd AED | - | PB (15 dogs) or Primidone (4 dogs) | PB (8 dogs) or Primidone (4 dogs) | PB or Primidone | PB (23 dogs) | PB (10 dogs) |
3 rd AED | - | - | - | - | - | - |
4 th AED | - | - | - | - | - | - |
No of dogs | 23 | 19 | 44 | 122 | 37 | 10 |
Period of treatment (months) | Approx. 6 | mean, 21; range, 7-61 | mean, 7.3 ± 0.6 | mean, 14.2 +/− 4.7 | mean, 15; range, 4-33 | median, 7; mean 7.8 |
Dose of AED(s) (mg/kg) | mean, 30.6; range, 26–35 PO BID | PBr: 17–58 PO SID; | PBr: 40–60 PO SID; | Doses were NA but adjusted according to the therapeutic serum levels and clinical response | PBr: mean, 20.75; range, 13–40 PO BID; PB: NA | PBr: 22 PO SID (dose increases occurred); |
PB and Primidone: NA but kept at maximum therapeutic doses | PB: 6–17 PO SID; | PB: median, 3.3; mean, 3.8 PO BID (dose was reduced by a mean of 50% in 7/10 dogs during the PBr treatment) | ||||
Primidone: 50–70 PO SID | ||||||
Pre-treatment SF (seizures/month) | mean, 5.4 +/mean, 14.2 +/−9.7 (recorded over a period of at least 6 weeks) | NA (but recorded over period of mean, 31; range, 8–79 m) | median, 3 (recorded over a period of mean 1.7 years) | NA | mean, 14.1 +/− 11.6 (recorded over a period of 0–12 m) | median, 27; mean 25; range 3–45 (recorded over a period of 5–72 m) |
Post-treatment SF (seizures/month) | mean, 1.2 +/− 2.4 | NA | median, 1.9 | - | mean, 6.6 +/− 5.7 | NA |
No of dogs that were failures | 3/23 (13%) | 6/19 (32%) | 5/12 (42%) | - | - | 3/10 (30%) |
No of dogs with >0% - <50% reduction in SF | 1/23 (4%) | 2/19 (10%) | 2/12 (16%) | - | 6/23 (26%) | - |
No of dogs with ≥50% - <100% reduction in SF | 5/23 (22%) | 7/19 (37%) | 5/12 (42%) | 88/122 (72%) | 11/23 (48%) | 3/10 (30%) |
No of dogs with 100% reduction in SF | 12/23 (52%) | 4/19 (21%) | - | - | 6/23 (26%) | 4/10 (40%) |
No of dogs with >30% reduction in SF | - | 17/19 (89%) | 7/12 (32%) | 88/122 (72%) | 23/23 (100%) | 7/10 (70%) |
95% CI successfully treated cases | 57% - 91% | 36% - 80% | 27% - 57% | 64% - 80% | 60% - 88% | 42% - 98% |
Overall evidence for/against recommending the use of an AED | Fair evidence for recommending the use of potassium bromide as a monotherapy AED. | |||||
Insufficient evidence for recommending the use of potassium bromide as an adjunct AED. | ||||||